0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Siglec-10

Siglec-10

Siglec-10 Molecule Information

Name:Sialic acid-binding Ig-like lectin 10
Target Synonym:Siglec-like protein 2;SLG2;Siglec-10;SIGLEC10
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase ?

Siglec-10 Part of Bioactivity data

SI0-H82F6-ELISA
Biotinylated Human Siglec-10, Fc,AvitagBiotinylated Human Siglec-10, Fc,Avitag (Cat. No. SI0-H82F6) ELISA bioactivity

Immobilized Biotinylated Human Siglec-10, Fc,Avitag (Cat. No. SI0-H82F6) at 5 μg/mL (100 μL/well) on Streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate, can bind Anti-Human Siglec-10 MAb, human IgG with a linear range of 0.6-20 ng/mL (QC tested).

SI0-H82E3-ELISA
Biotinylated Human Siglec-10, His,AvitagBiotinylated Human Siglec-10, His,Avitag (Cat. No. SI0-H82E3) ELISA bioactivity

Immobilized Biotinylated Human Siglec-10, His,Avitag (Cat. No. SI0-H82E3) at 5 μg/mL (100 μL/well) on Streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate, can bind Anti-Human Siglec-10 MAb, human IgG with a linear range of 0.6-20 ng/mL (QC tested).

Siglec-10 Protein Product ListCompare or Buy

Siglec-10 Molecule Synonym Name

SIGLEC10,MGC126774,PRO940,Siglec10,SLG2

Siglec-10 Molecule Background

The siglecs (sialic acid-binding Ig-like lectins) are a distinct subset of the Ig superfamily with adhesion-molecule-like structure. We describe here a novel member of the siglec protein family that shares a similar structure including five Ig-like domains, a transmembrane domain, and a cytoplasmic tail containing two ITIM-signaling motifs. Siglec-10 was identified through database mining of an asthmatic eosinophil EST library. The Siglec-10-VAP-1 interaction seems to mediate lymphocyte adhesion to endothelium and has the potential to modify the inflammatory microenvironment via the enzymatic end products.

Siglec-10 References

Siglec-10 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CD24-Fc CD24-Fc; CD24-Fc-IgG; HAS-CD24 Phase Ⅲ OncoImmune, National Institute of Neurological Disorders and Stroke, University of Michigan, The Ohio State University Comprehensive Cancer Center Graft versus host disease, Coronavirus Disease 2019 (COVID-19) Details

This web search service is supported by Google Inc.

totop